Disruption of <i>SUV39H1</i> -Mediated H3K9 Methylation Sustains CAR T-cell Function
Nayan Jain(Memorial Sloan Kettering Cancer Center), Michel Sadelain(Memorial Sloan Kettering Cancer Center)
Cited by 77
Related Papers
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
|Cancer Discovery|2021|551
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape
|Molecular Therapy|2018|256
CAR therapy: the CD19 paradigm
|Journal of Clinical Investigation|2015|228
TET2 guards against unchecked BATF3-induced CAR T cell expansion
|Nature|2023|142